Tennessee Senate Bill SB2279

Tennessee 2025-2026 Regular Session

• Introduced: 2/2/26
• Engrossed: 4/2/26
• Enrolled: 4/8/26
• Passed: 4/27/26
• Chaptered: 5/4/26

Caption

AN ACT to amend Tennessee Code Annotated, Title 63 and Title 68, relative to pain management.

Summary

SB2279 revises Tennessee’s pain management oversight laws in Titles 63 and 68. The bill changes how the Department of Health identifies and monitors “high-risk prescribers,” requiring the department to use clinical outcomes such as patient overdoses, publish the criteria used to make that determination, and conduct selected chart reviews and investigations of identified providers. It also shortens one lookback period from a four-week standard to a thirty-day standard and adds a process for expunging a prescriber’s high-risk designation if the prescriber completes required education and either the overdoses were not tied to substances the prescriber prescribed or the prescriber is not identified again for two consecutive years.

Impact

The bill affects prescribers, pain management specialists, and pain management clinics by changing oversight, reporting, and administrative procedures. It allows a pain management specialist to temporarily cover as medical director for an absent clinic director without being physically present, removes that temporary service from the four-clinic medical-director cap, and eliminates a notice requirement to the department for that temporary substitution. It also reduces the frequency of required clinic reporting from weekly to quarterly and authorizes advisory private letter rulings for affected licensees, while requiring the department to publish clinic inspection criteria online. Overall, the act expands transparency in some areas while easing certain operational burdens on pain management clinics and specialists.

Sentiment

The bill appears to have been broadly supported. It passed the Senate Health and Welfare Committee unanimously and cleared the Senate floor without opposition on third consideration, then passed final House consideration with a substantial majority. The voting pattern suggests the legislation was viewed as a practical regulatory update rather than a controversial policy shift.

Contention

There is little evidence of major controversy in the available record, but the bill does touch on two potentially sensitive areas: stronger state scrutiny of prescribers associated with overdoses, and reduced administrative burdens for pain management clinics. Any tension likely centered on balancing opioid/pain-treatment oversight and patient safety against concerns that existing reporting and medical-director rules may be too rigid or burdensome for providers. The unanimous committee vote and strong floor support indicate those issues were resolved in favor of the bill’s compromise approach.